WO2001022934A3 - Delivery of small doses of ingestible treatments - Google Patents

Delivery of small doses of ingestible treatments Download PDF

Info

Publication number
WO2001022934A3
WO2001022934A3 PCT/US2000/025882 US0025882W WO0122934A3 WO 2001022934 A3 WO2001022934 A3 WO 2001022934A3 US 0025882 W US0025882 W US 0025882W WO 0122934 A3 WO0122934 A3 WO 0122934A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
animal
treatment
gustatory
delivery
Prior art date
Application number
PCT/US2000/025882
Other languages
French (fr)
Other versions
WO2001022934A2 (en
Inventor
Quing Non Yng-Wong
Original Assignee
Yng Wong Quing Non
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yng Wong Quing Non filed Critical Yng Wong Quing Non
Priority to AU77068/00A priority Critical patent/AU7706800A/en
Publication of WO2001022934A2 publication Critical patent/WO2001022934A2/en
Publication of WO2001022934A3 publication Critical patent/WO2001022934A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Treatment of human or animal diseases, illnesses, and conditions may be effectively practiced by administering extremely small dosages of bioactive substances which cause a 'trigger effect'. By neurostimulating the human's or animal's brain one effects a positive physical manifestation by substantially solely influencing the human's or animal's gustatory, or gustatory and olfactory, receptors. This is typically accomplished using a delivery vehicle (such as a wafer, lozenge, or capsule) containing only between about 8 micrograms and 0.5 picograms (or about 5-10 microliters of about 6.7 x 10-8 to 2.5 x 10-15 molar solution) of the bioactive substance, and treatment is essentially as effective as if the same bioactive substance was used in conventional treatment of a patient, through the bloodstream.
PCT/US2000/025882 1999-09-24 2000-09-21 Delivery of small doses of ingestible treatments WO2001022934A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU77068/00A AU7706800A (en) 1999-09-24 2000-09-21 Delivery of small doses of ingestible treatments

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15558699P 1999-09-24 1999-09-24
US60/155,586 1999-09-24
US66246800A 2000-09-15 2000-09-15
US09/662,468 2000-09-15

Publications (2)

Publication Number Publication Date
WO2001022934A2 WO2001022934A2 (en) 2001-04-05
WO2001022934A3 true WO2001022934A3 (en) 2001-08-16

Family

ID=26852432

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025882 WO2001022934A2 (en) 1999-09-24 2000-09-21 Delivery of small doses of ingestible treatments

Country Status (2)

Country Link
AU (1) AU7706800A (en)
WO (1) WO2001022934A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001622B1 (en) 2003-06-30 2006-02-21 Robert Berndt Composition and method for treatment and prevention of pruritis
DE10354667A1 (en) * 2003-11-22 2005-07-14 Phytovisions Gmbh & Co. Kg Composition containing extracts of Lycium and Schisandra, useful in cosmetics, foods and supplements, have antistress and anti-ageing activities, lack potentially harmful lignans and schisandrins
US8067045B2 (en) 2005-03-03 2011-11-29 Pharmanex, Llc Nutritional formulations and associated methods
CA2639895C (en) 2007-10-05 2014-06-10 David Rowland Energizing compositions comprising goji, red clover and polygonum multiflorum, and uses thereof
US20150328272A1 (en) * 2012-06-22 2015-11-19 Golden Biotechnology Corporation Compositions for Improving the Development of Arteriosclerotic Vascular Diseases
CN102716346B (en) * 2012-06-28 2014-05-07 任兆禄 Detoxification and drug-relief medicine
EP2866817A4 (en) * 2012-07-06 2016-04-20 Omeros Corp Andrographis paniculata compositions and methods for treatment of addictions
US20150297652A1 (en) * 2012-11-20 2015-10-22 Vita Naturale, Llc Compositions and methods for their dermatological use
US9737582B2 (en) 2014-05-08 2017-08-22 Access Business Group International Llc Method for improving memory of a subject using a composition comprising Cistanche and Ginkgo extracts
JP7032855B2 (en) * 2016-10-04 2022-03-09 コンビ株式会社 Compositions for altering the expression of clock genes
KR101952648B1 (en) * 2017-08-03 2019-02-27 국가식품클러스터지원센터 The Inhibitory Effects of Amomum vilosum Loureiro Extracts and Composition Containing the Extract as Effective Ingredient
SG11202003122XA (en) * 2017-10-19 2020-05-28 Univ Yale Inhibition of androgen receptor by extracts of medicinal herbs and compositions thereof
CN108813608A (en) * 2018-05-25 2018-11-16 陕西黄龙国寿堂生物工程有限公司 A kind of production method of sea-buckthorn wilsonii cream
US20210052687A1 (en) * 2018-07-24 2021-02-25 "Bio 8", Limited Liability Company Plant extract-based biologically active supplement having antibacterial, antiviral and antifungal action
EP3979817A4 (en) * 2019-06-06 2022-12-21 Sami-Sabinsa Group Limited Composition for prostaglandin transporter inhibition and related therapeutic applications
CN110907574B (en) * 2019-11-06 2022-04-05 桂林三金药业股份有限公司 Quality control method, quality control spectrogram and construction method of traditional Chinese medicine composition
CN110999860B (en) * 2019-12-17 2021-12-17 田继兰 Method for researching insomnia resistance action mechanism of Sugelia based on amino acid metabonomics
TWI800740B (en) * 2020-06-30 2023-05-01 豐華生物科技股份有限公司 Composition for facilitating defecation and uses thereof
CN115501273A (en) * 2021-06-23 2022-12-23 广西大学 Application of traditional Chinese medicine compound effective extract in preparation of medicine for resisting eimeria tenella
CN114010743B (en) * 2021-10-18 2023-09-05 无限极（中国）有限公司 Chinese herbal medicine composition for improving hearing impairment and preparation method and application thereof
US20230165925A1 (en) * 2021-12-01 2023-06-01 Meyer Health Jiangsu Co., Ltd. Antidepressant food and method for preparing the same
CN114747697B (en) * 2022-04-20 2023-09-26 汕头大学 Scylla paramamosain soft pellet compound feed with long shelf life and preparation method thereof
CN115054589B (en) * 2022-05-31 2023-10-24 海南海药本草生物科技有限公司 Oral instant film agent containing L-borneol and preparation method thereof
CN115177690B (en) * 2022-07-07 2023-09-19 张振录 Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof
CN115177657B (en) * 2022-08-15 2023-08-04 正大青春宝药业有限公司 Application of selfheal in improving safety of stephania tetrandra-containing medicament
CN115154521B (en) * 2022-08-23 2023-07-25 刘爱民 Composition and preparation for treating psoriasis caused by external cold and internal heat and preparation method
CN115364154A (en) * 2022-10-18 2022-11-22 江西中医药大学 Preparation method of traditional Chinese medicine composition, traditional Chinese medicine tea and traditional Chinese medicine tea bag
CN115581718B (en) * 2022-11-24 2023-03-14 四川省畜牧科学研究院 Phyllanthus emblica and groundsel composition and antifungal application thereof
CN116693716B (en) * 2023-04-28 2024-07-19 湖北医药学院 Radix tinosporae polysaccharide and preparation method and application thereof
CN116327830B (en) * 2023-05-04 2024-04-12 海南医学院 Traditional Chinese medicine composition for resisting oxidization and regulating intestinal flora and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0567352A1 (en) * 1992-04-24 1993-10-27 Wisconsin Alumni Research Foundation Use of 1-alpha,24(R)-dihydroxy-22(E)-dehydro-vitamin D3 for the manufacture of a medicament for the treatment of osteoporosis
US5431881A (en) * 1993-12-10 1995-07-11 Palacios; Henry J. Treatment of hair loss and dermatological problems
US5837254A (en) * 1996-11-14 1998-11-17 Chen; Yu Method of treating candida and cryptococcus fungal infections by administering gentian
WO2000054794A1 (en) * 1999-03-18 2000-09-21 Yng Wong Quing Non Wafer delivery system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0567352A1 (en) * 1992-04-24 1993-10-27 Wisconsin Alumni Research Foundation Use of 1-alpha,24(R)-dihydroxy-22(E)-dehydro-vitamin D3 for the manufacture of a medicament for the treatment of osteoporosis
US5431881A (en) * 1993-12-10 1995-07-11 Palacios; Henry J. Treatment of hair loss and dermatological problems
US5837254A (en) * 1996-11-14 1998-11-17 Chen; Yu Method of treating candida and cryptococcus fungal infections by administering gentian
WO2000054794A1 (en) * 1999-03-18 2000-09-21 Yng Wong Quing Non Wafer delivery system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAVEZ M L ET AL: "HOMEOPATHY", HOSPITAL PHARMACY,LIPPINCOTT, PHILADELPHIA,US, vol. 33, no. 1, 1998, pages 41 - 50, XP000925059, ISSN: 0018-5787 *
NEGTIEN G; TRAISNEL M; VERAIN A: "MEDICAMENTS HOMEOPATIQUES", 1986, GALENICA, FR, PARIS, TECHNIQUE ET DOCUMENTATION, XP002162252 *

Also Published As

Publication number Publication date
AU7706800A (en) 2001-04-30
WO2001022934A2 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
WO2001022934A3 (en) Delivery of small doses of ingestible treatments
ES2526707T3 (en) Purification and stabilization of peptides and proteins in pharmaceutical agents
ES2137948T3 (en) ADVANCED SYSTEM OF ADMINISTRATION OF MEDICINES AND METHOD OF TREATMENT OF PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMACEPINE.
NO964864D0 (en) Oral liquid alendronate preparations
DE60100994D1 (en) Transdermal therapeutic system for the achievement of high plasma levels of rotigotine in the therapy of Parkinson's disease
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
CA2046014A1 (en) Reduction or prevention of skin irritation by drugs
AU4787996A (en) Calcitonin salmon analogues, their preparation, medicinal useand use as analytical agents
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
US4816439A (en) The use of human growth hormone for the treatment of intoxicated individuals
EP0055118A1 (en) Arthritis treatment
CA2296231C (en) Composition and method for treating common viral infections
JP3263598B2 (en) Bioactive peptide composition for nasal absorption
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
WO2002006343A3 (en) Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
CZ289788B6 (en) Topic preparation for introducing peptide medicaments into live organisms
JPS63303931A (en) Drug preparation for transnasal administration having growth hormone releasing activity
JP2004315470A (en) Pharmaceutical preparation containing sodium iodide
HUP9900521A2 (en) Process for preparing solid dosage forms of very low-dose drugs
WO2002030955A3 (en) Tetrapeptide stimulating functional activity of hepatocytes and its therapeutical use
CA1286224C (en) Use of human growth hormone for the treatment of intoxicated individuals
Turner et al. Will anything work for the common cold?
KR920700041A (en) Therapeutic Compounds and Their Composition and Uses
RU2000108989A (en) METHOD FOR PREVENTION AND TREATMENT OF CAVIAR RESPIRATORY DISEASES
PT1265629E (en) USE OF GROWTH HORMONE IN LOW DOSE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP